Information de reference pour ce titreAccession Number: | 00000620-200811310-00020.
|
Author: | GLASGOW, CONNIE G. a; TAVEIRA-DASILVA, ANGELO M. a; DARLING, THOMAS N. b; MOSS, JOEL a
|
Institution: | (a)Translational Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA (b)Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
|
Title: | |
Source: | Annals of the New York Academy of Sciences. 1131(1):206-214, May 2008.
|
Abstract: | Lymphangioleiomyomatosis (LAM) is a rare, multisystem disease affecting primarily premenopausal women. The disease is characterized by cystic lung disease, at times leading to respiratory compromise, abdominal tumors (in particular, renal angiomyolipomas), and involvement of the axial lymphatics (e.g., adenopathy, lymphangioleiomyomas). Disease results from the proliferation of neoplastic cells (LAM cells), which, in many cases, have a smooth muscle cell phenotype, express melanoma antigens, and have mutations in one of the tuberous sclerosis complex genes (TSC1 or TSC2). In the lung, LAM cells found in the vicinity of cysts are, at times, localized in nodules and may be responsible for cyst formation through the production of proteases. Lymphatic channels, expressing characteristic lymphatic endothelial cell markers, are found within the LAM lung nodules. LAM cells may also be localized within the walls of the axial lymphatics, and, in some cases, penetrate the wall and proliferate in the surrounding adipose tissue. Consistent with extensive lymphatic involvement in LAM, the serum concentration of VEGF-D, a lymphangiogenic factor, is higher in LAM patients than in healthy volunteers.
Copyright 2008 by the New York Academy of Sciences. All rights reserved.
|
Author Keywords: | lymphangiogenesis; metastasis; lymphangioleiomyomatosis; VEGF-D; VEGF-C.
|
References: | 1. KITAICHI, M., K. NISHIMURA, et al. 1995. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am. J. Respir. Crit. Care Med. 151: 527-533.
2. URBAN, T., R. LAZOR, et al. 1999. Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Medicine 78: 321-337.
3. RYU, J.H., J. MOSS, et al. 2006. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am. J. Respir. Crit. Care Med. 173: 105-111.
4. CHU, S.C., K. HORIBA, et al. 1999. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 115: 1041-1052.
5. TAYLOR, J.R., J. RYU, et al. 1990. Lymphangioleiomyomatosis: clinical course in 32 patients. N. Engl. J. Med. 323: 1254-1260.
6. JOHNSON, S.R. & A.E. TATTERSFIELD. 2002. Lymphangioleiomyomatosis. Semin. Respir. Crit. Care Med. 23: 85-92.
7. HAYASHIDA, M., K. SEYAMA, et al. 2007. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 12: 523-530.
8. TAVEIRA-DASILVA, A.M., W.K. STEAGALL, et al. 2006. Lymphangioleiomyomatosis. Cancer Control 13: 276-285.
9. JOHNSON, S.R., C.I. WHALE, et al. 2004. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 59: 800-803.
10. TAVEIRA-DASILVA, A.M., C. HEDIN, et al. 2001. Reversible airflow obstruction: proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 164: 1072-1076.
11. AVILA, N.A., C.C. CHEN, et al. 2000. Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 214: 441-446.
12. FERRANS, V.J., Z.-X. YU, et al. 2000. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J. Nippon Med. Sch. 67: 311-329.
13. MATSUI, K., A. TATSUGUCHI, et al. 2000. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum. Pathol. 31: 1242-1248.
14. MATSUI, K., W.K. RIEMENSCNEIDER, et al. 2000. Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis: immunohistochemical and electron microscopic study. Arch. Pathol. Lab. Med. 124: 1642-1648.
15. MATSUMOTO, Y., K. HORIBA, et al. 1999. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol. 21: 327-336.
16. OHORI, N.P., S.A. YOUSEM, et al. 1991. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am. J. Clin. Pathol. 96: 529-535.
17. MATSUI, K., K. TAKEDA, et al. 2000. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy: an immunohistochemical study. Am. J. Respir. Crit. Care Med. 161: 1002-1009.
18. VALENCIA, J.C., G. PACHECO-RODRIGUEZ, et al. 2006. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol. 35: 40-47.
19. VALENCIA, J.C., K. MATSUI, et al. 2001. Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis. J. Invest. Med. 49: 421-433.
20. SHAPIRO, S.D. 2006. Chairman's summary. Proc. Am. Thorac. Soc. 3: 397-400.
21. PARKS, W.C. & S. SHAPIRO. 2001. Review: matrix metalloproteinases in lung biology. Respir. Res. 2: 10-19.
22. MATSUI, K., K. TAKEDA, et al. 2000. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch. Pathol. Lab. Med. 124: 267-275.
23. HAYASHI, T., M.V. FLEMING, et al. 1997. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum. Pathol. 28: 1071-1078.
24. ZHE, X., Y. YANG, et al. 2003. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am. J. Respir. Cell Mol. Biol. 28: 504-511.
25. KRYMSKAYA, V.P. & J.M. SHIPLEY. 2003. Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am. J. Respir. Cell Mol. Biol. 28: 546-550.
26. MOSS, J., N.A. AVILA, et al. 2001. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am. J. Respir. Crit. Care Med. 163: 669-671.
27. COSTELLO, L.C., T.E. HARTMAN, et al. 2000. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin. Proc. 75: 591-594.
28. FRANZ, D.N., A. BRODY, et al. 2001. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am. J. Respir. Crit. Care Med. 164: 661-668.
29. SMOLAREK, T.A., L.L. WESSNER, et al. 1998. Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am. J. Hum. Genet. 62: 810-815.
30. CARSILLO, T., A. ASTRINIDIS, et al. 2000. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. USA 97: 6085-6090.
31. SATO, T., K. SEYAMA, et al. 2002. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J. Hum. Genet. 47: 20-28.
32. GONCHAROVA, E.A., D.A. GONCHAROV, et al. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277: 30958-30967.
33. TEE, A.R., D.C. FINGAR, et al. 2002. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA 99: 13571-13576.
34. TEE, A.R., B.D. MANNING, et al. 2003. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13: 1259-1268.
35. MAZIAK, D.E., S. KESTON, et al. 1996. Extrathoracic angiomyolipomas in lymphangioleiomyomatosis. Eur. Respir. J. 9: 402-405.
36. KERR, L.A., M.L. BLUTE, et al. 1993. Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis: forme fruste of tuberous sclerosis? Urology 41: 440-444.
37. KELLY, J. & J. MOSS. 2001. Lymphangioleiomyomatosis. Am. J. Med. Sci. 321: 17-25.
38. MCINTOSH, G.S., S.H. DUTOIT, et al. 1989. Multiple unilateral renal angiomyolipomas with regional lymphangioleiomyomatosis. J. Urol. 142: 1305-1307.
39. HENSKE, E.P., H.P. NEUMANN, et al. 1995. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 13: 295-298.
40. KEBRIA, M., D. BLACK, et al. 2007. Primary retroperitoneal lymphangioleiomyomatosis in a postmenopausal woman: a case report and review of the literature. Int. J. Gynecol. Cancer 17: 528-532.
41. LAM, B., G.C. OOI, et al. 2003. Extrapulmonary presentation of asymptomatic pulmonary lymphangioleiomyomatosis. Respirology 8: 544-547.
42. JOHNSON, S.R. 2006. Lymphangioleiomyomatosis. Eur. Respir. J. 27: 1056-1065.
43. MATSUI, K., M.B. BEASLEY, et al. 2001. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am. J. Surg. Pathol. 29: 1356-1366.
44. AVILA, N.A., J.A. KELLY, et al. 2000. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 216: 147-153.
45. TAVEIRA-DASILVA, A.M., M.P. STYLIANOU, et al. 2004. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126: 1867-1874.
46. BISSLER, J.J. & J.C. KINGSWOOD. 2004. Renal angiomyolipomata. Kidney Int. 66: 924-934.
47. RYU, J.H., C.H. DOERR, et al. 2003. Chylothorax in lymphangioleiomyomatosis. Chest 123: 623-627.
48. ALMOOSA, K.F., J.H. RYU, et al. 2006. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 129: 1274-1281.
49. AVILA, N.A., A.J. DWYER, et al. 2006. CT of pleural abnormalities in lymphangioleiomyomatosis and comparison of pleural findings after different types of pleurodesis. AJR Am. J. Roentgenol. 186: 1007-1012.
50. AVILA, N.A., J.A. KELLY, et al. 2002. Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 223: 189-197.
51. STEAGALL, W.K., C.G. GLASGOW, et al. 2007. Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 293: L800-L808.
52. BITTMAN, I., B. ROLF, et al. 2003. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum. Pathol. 34: 95-98.
53. KARBOWNICZEK, M., A. ASTRINIDIS, et al. 2003. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am. J. Respir. Crit. Care Med. 167: 976-982.
54. CROOKS, D.M., G. PACHECO-RODRIGUEZ, et al. 2004. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. USA 101: 17462-17467.
55. TAI, H.-C., J.-W. LIN, et al. 2006. Pulmonary lymphangioleiomyomatosis followed by a localized retroperitoneal lymphangioleiomyoma. A.P.M.I.S. 114: 821-824.
56. CORNOG, J.L., JR. & H.T. ENTERLINE. 1966. Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer 19: 1909-1930.
57. WOODRING, J.H., R.S. HOWARD II, et al. 1994. Massive low-attenuation mediastinal, retroperitoneal, and pelvic lymphadenopathy on CT from lymphangioleiomyomatosis case report. Clinical Imaging 18: 7-11.
58. PALLISA, E., P. SANZ, et al. 2002. Lymphangioleiomyomatosis: pulmonary and abdominal findings with pathologic correlation. RadioGraphics 22: S185-S198.
59. AVILA, N.A., J. BECHTLE, et al. 2001. Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. Radiology 221: 415-421.
60. AVILA, N.A., A.J. DWYER, et al. 2005. Sonography of lymphangioleiomyoma in lymphangioleiomyomatosis: demonstration of diurnal variation in lesion size. AJR Am. J. Roentgenol. 184: 459-464.
61. LEUNG, A.K.C., W.L.M. ROBSON. 2007. Tuberous sclerosis complex: a review. J. Pediatr Health Care 21: 108-114.
62. ARBISER, J.L., D. BRAT, et al. 2002. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J. Am. Acad. Dermatol. 46: 376-380.
63. AVILA, N.A., A.J. DWYER, et al. 2007. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology 242: 277-285.
64. WEBB, D.W., A. CLARKE, et al. 1996. The cutaneous features of tuberous sclerosis: a population study. Br. J. Dermatol. 135: 1-5.
65. NGUYEN-VU, P.-A., I. FACKER et al. 2001. Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. J. Cutan. Pathol. 28: 470-475.
66. LI, S., F. TAKEUCHI, et al. 2005. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J. Exp. Med. 202: 617-624.
67. NICKEL, W.R. & W.B. REED. 1962. Tuberous sclerosis: special reference to the microscopic alterations in the cutaneous hamartomas. Arch. Dermatol. 85: 89-106.
68. SANCHEZ, N.P., M.R. WICK, et al. 1981. Adenoma sebaceum of Pringle: a clinicopathologic review, with a discussion of related pathologic entities. J. Cutan. Pathol. 8: 395-403.
69. HIRAKAWA, S., Y.-K. HONG, et al. 2003. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am. J. Pathol. 162: 575-586.
70. STACKER, S.A., M.E. BALDWIN, et al. 2002. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 16: 922-934.
71. SLEEMAN, J.P. 2000. The lymph node as a bridgehead in the metastatic dissemination of tumors. Rec. Results Cancer Res. 157: 55-81.
72. KUMASAKA, T., K. SEYAMA, et al. 2004. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am. J. Surg Pathol. 8: 1007-1015.
73. KUMASAKA, T., K. SEYAMA, et al. 2005. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am. J. Surg. Pathol. 29: 1356-1366.
74. SEYAMA, K., T. KUMASAKA, et al. 2006. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymph. Res. Biol. 3: 143-152.
|
Language: | English.
|
Document Type: | Part III. Biological Principle in Lymphedema Diagnosis and Management.
|
Journal Subset: | Clinical Medicine. Behavioral & Social Sciences. Life Sciences. Physical Science & Engineering.
|
ISSN: | 0077-8923
|
NLM Journal Code: | 5nm, 7506858
|
Annotation(s) | |
|
|